AstraZeneca pays to settle Tropol XL antitrust case
Tuesday, 27 September 2011
Ron Knox
Drug maker AstraZeneca has agreed to pay US$20 million to settle a potential class action lawsuit accusing the company of using sham patent litigation to unfairly monopolise the market for the branded heart disease medication Tropol XL.
Subscription required to view this article
This content can only be accessed by GCR subscribers.
A subscription includes 10 issues of the journal, 2 signature surveys - The GCR100 and Rating Enforcement, 10 GCR special reports and full access to current print and online content.
Please note: If you would like online access to all archived content, you will need a Premium subscription.
If you are a GCR subscriber, please login to access this content:
Comments
You must Subscribe or Log In to make comments.
Comment Terms & Conditions
Back to top